Antiemetics Drugs Market Size & Growth Forecast 2027–2036, By Segments (End-use, Application, Drug Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Antiemetics Drugs Market size was more than USD 8.8 billion in 2026 and is set to grow at a 5.61% CAGR between 2027 and 2036, surpassing USD 15.19 billion by 2036. The industry revenue for 2027 is assessed at USD 9.22 billion.
Get more details on this report
Request Free Sample ReportAntiemetics Drugs Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for a 38.71% share in 2026, supported by established oncology care, specialist access, and routine supportive treatment protocols.
- Asia Pacific is projected to grow at a 6.89% CAGR, fueled by expanding cancer care services, surgical volumes, and broader supportive medicine access.
Segment Momentum
- Retail pharmacies held a 50.78% market share in 2026 because they are the primary channel for prescription fulfillment, refills, and convenient access to antiemetic treatments in outpatient settings.
- Post-operative surgery is the fastest-growing application as healthcare providers increasingly prioritize nausea and vomiting prevention to improve patient comfort, recovery management, and discharge readiness after procedures.
Market Expansion Drivers
- Increasing cancer prevalence driving demand for chemotherapy-induced nausea management therapies.
- Rising gastroenteritis incidence expanding utilization of antiemetic treatment solutions globally.
- Growing approvals of generic and novel antiemetic drugs improving treatment accessibility.
Leading Market Participants
- Leading companies in the antiemetics drugs market include Pfizer Inc. (United States), Merck & Co., Inc. (United States), Johnson & Johnson (United States), GlaxoSmithKline plc (United Kingdom), Astellas Pharma Inc. (Japan), Glenmark Pharmaceuticals Ltd. (India), Viatris Inc. (United States), Baxter International Inc. (United States), Cipla Ltd. (India), Novartis AG (Switzerland).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 8.8 billion
- 2027 Estimated Market Size: USD 9.22 billion.
- Projected Market Size: USD 15.19 billion by 2036
- Growth Forecast: 5.61% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Retail Pharmacy (End-use) | Chemotherapy (Application) | Serotonin-receptor Antagonists (Drug Type)
- Emerging Opportunity Segment: Retail Pharmacy (End-use) | Post Operative Surgery (Application) | Serotonin-receptor Antagonists (Drug Type)
Market Growth Drivers and Industry Trends
Increasing cancer prevalence driving demand for chemotherapy-induced nausea management therapies
Increasing cancer prevalence will drive the antiemetics drugs market growth as chemotherapy and other cancer treatments can produce nausea and vomiting that require effective supportive care. Antiemetic therapies help patients manage these treatment-related effects, supporting adherence to cancer treatment regimens and improving overall treatment tolerance. The expanding use of systemic cancer therapies across different disease settings is consequently increasing the need for nausea and vomiting management, while ongoing efforts to improve supportive oncology care are encouraging broader use of antiemetic treatment options.
Rising gastroenteritis incidence expanding utilization of antiemetic treatment solutions globally
Rising gastroenteritis incidence will boost the antiemetics drugs market demand as nausea and vomiting associated with gastrointestinal infections can create a need for symptom management. Antiemetic treatments can help control these symptoms and support patient comfort, particularly when vomiting interferes with fluid intake and routine care. Greater utilization of healthcare services for gastrointestinal illnesses, together with the need to manage acute symptoms across different patient populations, is supporting the application of antiemetic therapies beyond oncology-related treatment settings.
Growing approvals of generic and novel antiemetic drugs improving treatment accessibility
Growing approvals of generic and novel therapies are strengthening the antiemetics drugs market by expanding the range of available treatment options for nausea and vomiting. Generic medicines can improve access by providing additional therapeutic alternatives, while novel products can introduce differentiated mechanisms, formulations, or administration approaches that address unmet treatment needs. A broader competitive and therapeutic landscape can also support wider adoption across healthcare settings by giving clinicians greater flexibility when selecting antiemetic treatments according to patient requirements and the underlying cause of symptoms.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing cancer prevalence driving demand for chemotherapy-induced nausea management therapies | 1.80% | High | North America, Asia Pacific | High | Near Term |
| Rising gastroenteritis incidence expanding utilization of antiemetic treatment solutions globally | 1.50% | Moderate | Asia Pacific, Latin America | High | Near Term |
| Growing approvals of generic and novel antiemetic drugs improving treatment accessibility | 1.30% | High | North America, Europe | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
In the antiemetics drugs market, North America held the largest share of 38.71% in 2026, reflecting the region’s well-established healthcare infrastructure, broad access to pharmaceutical treatments, and high demand for therapies that manage nausea and vomiting associated with cancer treatment, surgery, and other medical conditions. Strong clinical care networks and continued advances in supportive therapies contribute to consistent utilization of antiemetic medications. The region’s established oncology and surgical care systems, combined with growing attention to treatment tolerability and patient quality of life, continue to support market development.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is projected to experience the fastest market growth, supported by expanding healthcare access, rising pharmaceutical consumption, and improving treatment capabilities across emerging economies. Increasing diagnosis and treatment of conditions requiring supportive care, along with greater availability of modern medicines, is broadening the patient base for antiemetic therapies. Investments in healthcare infrastructure and the gradual expansion of specialized medical services are also improving access to treatment, creating stronger demand across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Treatment StandardizationGermany advances the antiemetics drugs market through standardized treatment protocols across oncology and postoperative care. German healthcare providers emphasize guideline-driven prescribing while evaluating therapies that improve patient comfort and reduce treatment-related complications.
France 🇫🇷
Integrated Patient ManagementFrance emphasizes coordinated patient management in the antiemetics drugs market by aligning supportive therapies with oncology and gastrointestinal care. French healthcare systems encourage treatment approaches that enhance quality of care and patient adherence.
Italy 🇮🇹
Hospital Care PrioritizationItaly reinforces the antiemetics drugs market through continued use of supportive medications in hospital-based oncology and surgical care. Italian healthcare providers focus on improving symptom management while balancing treatment effectiveness and clinical efficiency.
Japan 🇯🇵
Supportive Care EnhancementJapan focuses on strengthening supportive care by integrating antiemetics into comprehensive treatment pathways for chemotherapy and surgical patients. The country encourages optimization of therapeutic combinations that improve symptom control while maintaining patient safety.
South Korea 🇰🇷
Hospital Therapy AdoptionSouth Korea supports broader adoption of antiemetics across hospitals and specialty care centers as demand for advanced supportive therapies expands. Healthcare providers increasingly incorporate newer formulations that improve convenience and treatment consistency.
United States 🇺🇸
Oncology Care OptimizationThe U.S. antiemetics drugs market prioritizes supportive care for oncology, surgical, and hospital settings where effective nausea management improves treatment adherence. Healthcare providers continue adopting evidence-based antiemetic regimens tailored to diverse patient populations.
Segment Leadership and Growth Trends
Antiemetics Drugs Market Share (%), by End-use, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportEnd-use Segment Analysis: Retail Pharmacy (Largest & Fastest-Growing Segment)
Retail pharmacy segment dominated the antiemetics drugs market with a 50.78% share in 2026 and is also the fastest-growing end-use segment. Its strong position reflects the widespread need for accessible treatment of nausea and vomiting across outpatient settings, where patients can obtain antiemetic medicines without relying exclusively on hospital-based dispensing. Convenient access to medications, the prevalence of chemotherapy-related and postoperative nausea management outside inpatient care, and the continued expansion of community-based pharmaceutical services are supporting demand through retail pharmacy channels.
Application Segment Analysis: Chemotherapy (Largest Segment) vs Post Operative Surgery (Fastest-Growing Segment)
Chemotherapy segment accounted for the largest share of the antiemetics drugs market at 48.44% in 2026, supported by the frequent occurrence of nausea and vomiting associated with cancer treatment. Effective management of treatment-related gastrointestinal symptoms is an important part of supportive oncology care because it can improve treatment tolerance, maintain patient well-being, and reduce interruptions to therapy. Increasing emphasis on comprehensive cancer care and supportive treatment strategies continues to sustain demand for antiemetic therapies in chemotherapy applications.
Post operative surgery is expected to experience the fastest growth as healthcare providers place greater emphasis on preventing and controlling postoperative nausea and vomiting to improve patient comfort and facilitate smoother recovery. Effective antiemetic management can support earlier mobilization, improve patient satisfaction, and reduce complications associated with persistent nausea following procedures. Growing surgical volumes and increasing attention to enhanced recovery practices are contributing to broader adoption of antiemetic therapies in postoperative settings.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| End-use | Hospital & Clinics, Retail Pharmacy, Others | Retail Pharmacy | Retail Pharmacy |
| Application | Chemotherapy, Gastroenteritis, Post Operative Surgery, Others | Chemotherapy | Post Operative Surgery |
| Drug Type | Serotonin-receptor Antagonists, Anticholinergics, Dopamine Receptor Antagonists, Neurokinin Receptor Antagonists, Others | Serotonin-receptor Antagonists | Serotonin-receptor Antagonists |
Competitive Landscape and Market Positioning
Major players in the antiemetics drugs market:
1. Pfizer Inc. (United States)
2. Merck & Co. Inc. (United States)
3. Johnson & Johnson (United States)
4. GlaxoSmithKline plc (United Kingdom)
5. Astellas Pharma Inc. (Japan)
6. Glenmark Pharmaceuticals Ltd. (India)
7. Viatris Inc. (United States)
8. Baxter International Inc. (United States)
9. Cipla Ltd. (India)
10. Novartis AG (Switzerland)
Rising prevalence of chemotherapy-induced nausea and post-operative complications is driving innovation in the antiemetics drugs market. Pharmaceutical developers are introducing improved formulations and extended-release therapies designed to enhance patient comfort and treatment adherence. Increased focus on personalized care approaches and supportive oncology treatments is also influencing competitive developments across the antiemetics drugs market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. (United States) | |||||||
| Merck & Co. Inc. (United States) | |||||||
| Johnson & Johnson (United States) | |||||||
| GlaxoSmithKline plc (United Kingdom) | |||||||
| Astellas Pharma Inc. (Japan) | |||||||
| Glenmark Pharmaceuticals Ltd. (India) | |||||||
| Viatris Inc. (United States) | |||||||
| Baxter International Inc. (United States) | |||||||
| Cipla Ltd. (India) | |||||||
| Novartis AG (Switzerland). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Astellas Pharma Inc. | Oct-23 | Astellas Pharma presented preclinical research evaluating the protective effects of supportive antiemetics against zolbetuximab-induced gastric injury and emesis at the ESMO Congress 2023. The animal study validates co-administration protocols to manage drug-induced toxicities, optimizing adherence and patient survival outcomes within targeted oncology treatment regimens. |
| Glenmark Pharmaceuticals Ltd | Jan-23 | Glenmark Pharmaceuticals launched AKYNZEO I.V., a fixed-dose ready-to-dilute intravenous injection formulation in India, under an exclusive licensing agreement with Swiss drugmaker Helsinn. Combining fosnetupitant and palonosetron, this single-dose prophylactic infusion prevents both acute and delayed phases of chemotherapy-induced nausea and vomiting. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Antiemetics Drugs Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Route of Administration | Oral, Intravenous, Intramuscular, Transdermal, Rectal & Other Routes |
| Patient Age Group | Pediatric, Adult, Geriatric |
| Dosage Form | Tablets & Capsules, Oral Liquids, Injectable Formulations, Transdermal Patches, Suppositories & Other Forms |
Antiemetics Drugs Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Treatment Guideline Adoption and Prescribing Trends |
|
| Unmet Patient Needs and Therapy Gap Assessment |
|
| Biosimilar and Generic Erosion Outlook |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current revenue of the antiemetics drugs market?
What are the growth projections for the antiemetics drugs industry?
How is rising cancer prevalence shaping demand for antiemetic therapies?
How are generic and novel product approvals influencing the antiemetics drugs market?
Why do retail pharmacies dominate the antiemetics drugs market?
What is driving growth in post-operative surgery applications for antiemetic drugs?
How does North America maintain its leading position in antiemetics drugs?
What is driving antiemetics drugs adoption in Asia Pacific?
Which companies are driving growth in the antiemetics drugs landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization